
Chemours (CC) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.4B
Gross Profit
236.0M
17.25%
Operating Income
78.0M
5.70%
Net Income
-4.0M
-0.29%
EPS (Diluted)
$-0.03
Balance Sheet Metrics
Total Assets
7.4B
Total Liabilities
6.8B
Shareholders Equity
580.0M
Debt to Equity
11.75
Cash Flow Metrics
Operating Cash Flow
-104.0M
Free Cash Flow
-196.0M
Revenue & Profitability Trend
Chemours Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 5.8B | 6.0B | 6.8B | 6.3B | 5.0B |
Cost of Goods Sold | 4.6B | 4.7B | 5.2B | 5.0B | 3.9B |
Gross Profit | 1.2B | 1.3B | 1.6B | 1.4B | 1.1B |
Gross Margin % | 19.9% | 21.7% | 23.8% | 21.8% | 21.5% |
Operating Expenses | |||||
Research & Development | 109.0M | 108.0M | 118.0M | 107.0M | 93.0M |
Selling, General & Administrative | 585.0M | 1.3B | 710.0M | 592.0M | 527.0M |
Other Operating Expenses | 14.0M | 31.0M | 2.0M | 8.0M | 41.0M |
Total Operating Expenses | 708.0M | 1.4B | 830.0M | 707.0M | 661.0M |
Operating Income | 443.0M | -123.0M | 786.0M | 674.0M | 406.0M |
Operating Margin % | 7.7% | -2.0% | 11.6% | 10.6% | 8.2% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 264.0M | 208.0M | 163.0M | 185.0M | 210.0M |
Other Non-Operating Income | -52.0M | 13.0M | 118.0M | 187.0M | -17.0M |
Pre-tax Income | 127.0M | -318.0M | 741.0M | 676.0M | 179.0M |
Income Tax | 41.0M | -81.0M | 163.0M | 68.0M | -40.0M |
Effective Tax Rate % | 32.3% | 0.0% | 22.0% | 10.1% | -22.3% |
Net Income | 86.0M | -237.0M | 578.0M | 608.0M | 219.0M |
Net Margin % | 1.5% | -3.9% | 8.5% | 9.6% | 4.4% |
Key Metrics | |||||
EBITDA | 801.0M | 248.0M | 1.2B | 1.1B | 788.0M |
EPS (Basic) | $0.58 | $-1.60 | $3.72 | $3.69 | $1.33 |
EPS (Diluted) | $0.57 | $-1.60 | $3.65 | $3.60 | $1.32 |
Basic Shares Outstanding | 149494462 | 148912397 | 150046614 | 164943575 | 164681827 |
Diluted Shares Outstanding | 149494462 | 148912397 | 150046614 | 164943575 | 164681827 |
Income Statement Trend
Chemours Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 713.0M | 1.2B | 1.1B | 1.5B | 1.1B |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 619.0M | 509.0M | 509.0M | 644.0M | 449.0M |
Inventory | 1.5B | 1.4B | 1.4B | 1.1B | 939.0M |
Other Current Assets | 71.0M | 66.0M | 82.0M | 75.0M | 78.0M |
Total Current Assets | 3.0B | 3.8B | 3.2B | 3.3B | 2.6B |
Non-Current Assets | |||||
Property, Plant & Equipment | 8.2B | 7.9B | 8.0B | 7.8B | 8.1B |
Goodwill | 95.0M | 207.0M | 217.0M | 210.0M | 320.0M |
Intangible Assets | 3.0M | 3.0M | 13.0M | 6.0M | 14.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 750.0M | 620.0M | 675.0M | 492.0M | 326.0M |
Total Non-Current Assets | 4.5B | 4.4B | 4.4B | 4.2B | 4.4B |
Total Assets | 7.5B | 8.3B | 7.6B | 7.6B | 7.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.1B | 1.1B | 1.2B | 1.1B | 820.0M |
Short-term Debt | 107.0M | 106.0M | 92.0M | 84.0M | 78.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | 90.0M | 83.0M | 172.0M |
Total Current Liabilities | 1.8B | 2.5B | 1.9B | 1.9B | 1.4B |
Non-Current Liabilities | |||||
Long-term Debt | 4.2B | 4.2B | 3.8B | 3.9B | 4.2B |
Deferred Tax Liabilities | 35.0M | 44.0M | 61.0M | 49.0M | 36.0M |
Other Non-Current Liabilities | 114.0M | 113.0M | 109.0M | 63.0M | 68.0M |
Total Non-Current Liabilities | 5.1B | 5.0B | 4.6B | 4.6B | 4.8B |
Total Liabilities | 6.9B | 7.5B | 6.5B | 6.5B | 6.3B |
Equity | |||||
Common Stock | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M |
Retained Earnings | 1.7B | 1.8B | 2.2B | 1.7B | 1.3B |
Treasury Stock | 1.8B | 1.8B | 1.7B | 1.2B | 1.1B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 605.0M | 739.0M | 1.1B | 1.1B | 815.0M |
Key Metrics | |||||
Total Debt | 4.4B | 4.3B | 3.9B | 4.0B | 4.3B |
Working Capital | 1.2B | 1.3B | 1.3B | 1.5B | 1.2B |
Balance Sheet Composition
Chemours Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 86.0M | -237.0M | 578.0M | 608.0M | 219.0M |
Depreciation & Amortization | 301.0M | 307.0M | 291.0M | 317.0M | 320.0M |
Stock-Based Compensation | 15.0M | 18.0M | 27.0M | 34.0M | 16.0M |
Working Capital Changes | -1.1B | 620.0M | -103.0M | 21.0M | 356.0M |
Operating Cash Flow | -692.0M | 645.0M | 796.0M | 913.0M | 779.0M |
Investing Activities | |||||
Capital Expenditures | -360.0M | -370.0M | -307.0M | -277.0M | -267.0M |
Acquisitions | - | - | - | 0 | 0 |
Investment Purchases | - | - | - | -12.0M | - |
Investment Sales | - | - | - | - | 27.0M |
Investing Cash Flow | -355.0M | -221.0M | -287.0M | 220.0M | -234.0M |
Financing Activities | |||||
Share Repurchases | 0 | -69.0M | -495.0M | -173.0M | 0 |
Dividends Paid | -148.0M | -149.0M | -154.0M | -164.0M | -164.0M |
Debt Issuance | 699.0M | 771.0M | 105.0M | 741.0M | 800.0M |
Debt Repayment | -604.0M | -378.0M | -185.0M | -949.0M | -1.4B |
Financing Cash Flow | -45.0M | 153.0M | -737.0M | -577.0M | -887.0M |
Free Cash Flow | -993.0M | 186.0M | 448.0M | 537.0M | 540.0M |
Net Change in Cash | -1.1B | 577.0M | -228.0M | 556.0M | -342.0M |
Cash Flow Trend
Chemours Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
67.83
Forward P/E
6.33
Price to Book
9.24
Price to Sales
0.37
PEG Ratio
-0.11
Profitability Ratios
Profit Margin
-7.04%
Operating Margin
4.46%
Return on Equity
-85.27%
Return on Assets
2.98%
Financial Health
Current Ratio
1.68
Debt to Equity
1,845.61
Beta
1.59
Per Share Data
EPS (TTM)
$-2.74
Book Value per Share
$1.58
Revenue per Share
$39.02
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
cc | 2.2B | 67.83 | 9.24 | -85.27% | -7.04% | 1,845.61 |
Linde plc | 222.6B | 34.37 | 5.86 | 17.01% | 20.02% | 60.56 |
Sherwin-Williams | 91.5B | 36.39 | 20.70 | 62.43% | 11.03% | 308.57 |
Albemarle | 9.9B | 33.52 | 1.26 | -9.99% | -22.39% | 35.76 |
Eastman Chemical | 7.6B | 9.29 | 1.30 | 14.39% | 8.96% | 90.60 |
NewMarket | 7.4B | 15.62 | 4.60 | 33.74% | 17.28% | 56.98 |
Financial data is updated regularly. All figures are in the company's reporting currency.